The Haute Autorité de santé (HAS) announced in a press release on Tuesday September 20 that it had given its authorization for the use of three vaccines against Covid-19 adapted to the Omicron variant for the new booster vaccination campaign planned for autumn and Coupled with that against the flu.
This new booster dose will be recommended for people at risk of severe form, their entourage and caregivers. The HAS recommends “indifferently one of the three bivalent vaccines” – two invented by Pfizer-BioNTech, the third by Moderna – recently validated by the European Medicines Agency.
“Based on the available data and in an epidemic context marked by the majority circulation of the BA.5 sub-variant”the HAS recommends as an employer “preferably” one of these vaccines, all messenger RNA, for a new automatic booster dose. This recommendation applies regardless of the anti-Covid vaccine already administered to the person.
Vaccines updated every year
“Like seasonal influenza vaccines, updated each year to take into account the viruses that are most likely to circulate during the winter, bivalent mRNA vaccines are not new vaccines but vaccines adapted to the strains circulating »underlines the HAS in its press release.
These are the vaccines from Moderna and Pfizer-BioNTech targeting the original strain of the virus and the Omicron BA.1 variant, and the vaccine from Pfizer-BioNTech targeting the original strain and the BA.4 and BA subvariants .5 of Omicron.
At the same time, the HAS has its recommendation to couple the vaccination reminder campaign against Covid-19 with that of vaccination against influenza, which will start on October 18. A concomitant injection or the same day of the two vaccines is possible, she recalls.
“Immediately and because the number of cases of infections has started to rise again for a few days”, this health authority recommends not postponing the second booster dose in the over 60s and under 60s at risk of a severe form who have not received it within the recommended timeframe. It recalls the effectiveness of current vaccines (monovalent) against severe forms of Covid-19.